Global Attention Deficit Hyperactivity Disorder Market Size

Attention Deficit Hyperactivity Disorder Market Analysis

The attention deficit hyperactivity disorder market is expected to grow at a registered CAGR of 6.9% during the forecast period (2022-2027).

The attention deficit hyperactivity disorder (ADHD) market is significantly impacted as a result of the COVID-19 pandemic. Governments from various countries are taking steps to combat attention deficit hyperactivity disorder (ADHD) in children. According to the study titled "Behavioral Implications of the Covid-19 Process for Autism Spectrum Disorder, and Individuals' Comprehension of and Reactions to the Pandemic Conditions," published in the Frontier in Psychiatry in November 2020, during the Covid-19 outbreak, symptoms of children with attention deficit hyperactivity disorder (ADHD) worsened significantly. Due to the stress caused by the COVID-19 pandemic, patients with attention deficit hyperactivity disorder (ADHD) have become more vulnerable. Thus, the attention deficit hyperactivity disorder market is significantly impacted by COVID-19.

During the forecast period, the global attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to grow due to an increase in the prevalence of the disorder. For instance, as per a February 2021 published study titled, "The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis," the prevalence of persistent adult ADHD was 2.58%, and that of symptomatic adult ADHD was 6.76%, translating to 139.84 million and 366.33 million affected adults in 2020 globally. Thus, rising in the burden of ADHD is expected to rise in demand for its treatment anticipated to boost the market over the forecast period.

Furthermore, the growing emphasis on research and development is resulting in the development of effective ADHD treatments, which is contributing to market growth. For instance, according to the study titled "Neurofunctional and behavioral measures associated with fMRI-Neurofeedback learning in adolescents with Attention-Deficit/Hyperactivity Disorder," published in the NeuroImage Clinical in May 2020, a larger trial with 100 children with ADHD was funded by the Medical Research Council for GBP 1.3 million. New collaborations with the National Institute of Mental Health and Dresden University were also formed as a result of the work. Since then, the team has received funding (roughly GBP 2 million from the National Institute for Health Research, Action Medical Research) to test other brain-based therapies in ADHD, including non-invasive brain stimulation treatments like transcranial direct current stimulation and stimulation of the trigeminal nerve, which controls facial sensations. Such a development in a treatment option for ADHD treatment is expected to boost the market over the forecast period.

The ADHD market is expected to grow due to a rise in public awareness about mental health and increased government funding. The rising number of people suffering from a variety of mental health disorders, including attention-deficit/hyperactivity disorder (ADHD), has drawn the attention of governments all over the world, forcing them to take action. As per the Regional Development Australia updates in July 2021, in 2021-22, the New South Wales (NSW) Government has contributed USD 1.8 million in funding for the ADHD pilot program, with a total investment of USD 7.7 million for the trial a new model of care and management for children with behavioral issues including attention-deficit hyperactivity disorder (ADHD) in regional NSW over four years.

Moreover, during the forecast period, key companies focusing on research and development in the treatment of attention deficit hyperactivity disorder (ADHD) therapeutics are expected to drive the global attention deficit hyperactivity disorder (ADHD) therapeutics market. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a subsidiary in the United States, reported positive top-line results from phase 3 clinical trials evaluating the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.

Thus, the aforementioned factors are likely to drive the growth of the market during the forecast period. However, less availability of non-stimulant ADHD drugs and underdiagnosis of ADHD. Thus, these factors act as some of the major restraints to the studied market.